not yet widely accessible in local clinics
Graphical abstract Table 1
These figures exceed, by several-fold, the per-capita pharmaceutical budget in many health-care systems and underscore a critical, often overlooked question: not every individual with hepatic steatosis can, or should, receive high-cost pharmacotherapy
Last reviewed: June 28, 2026 Last updated: June 28, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
The variables most physicians miss full thyroid, hormones, ferritin, inflammation often reveal the actual bottleneck
Your provider will tell you when its safe to begin taking blood thinners or other medications again